SUBSCRIBE
SUBSCRIBE
News   Policy

GlaxoSmithKline (JOBS) Temporarily Withdraws Avodart Cancer Filing

November 23, 2009 | 
1 min read
Bookmark and Share

Reuters -- GlaxoSmithKline temporarily withdrew its application to U.S. regulators for a new use of its Avodart drug in preventing prostate cancer because of a technical problem with the file, it said on Monday.
Regulatory
GSK
MORE ON THIS TOPIC
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Breast cancer
AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee
May 1, 2026
 · 
3 min read
 · 
Tristan Manalac
Emblem design for airlines, airplane tickets, travel agencies. Airplane icon and destination arrow. Flags of the USA and Great Britain. 3D rendering
Huntington’s disease
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
April 30, 2026
 · 
2 min read
 · 
Heather McKenzie
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Schizophrenia
Patient death prompts FDA pause on Newron’s Phase 3 schizophrenia study
April 30, 2026
 · 
2 min read
 · 
Tristan Manalac
A flower in the middle of the desert
Adcomms
FDA’s end to 9-month adcomm drought a ‘narrow restart’
April 30, 2026
 · 
7 min read
 · 
Tristan Manalac